可切除非小细胞肺癌中源自SUVmax空间位置的影像特征与肿瘤侵袭性相关
本研究回顾性纳入244例术前行[18F]FDG PET/CT的可切除非小细胞肺癌患者,构建基于SUVmax相对肿瘤质心与周边位移的边界邻近评分(EPS),并在TCIA队列中外部验证。EPS在伴有淋巴血管侵犯、脏层胸膜侵犯和气道播散的肿瘤中显著升高(P < 0.001),是无进展生存期的独立预测因子(HR = 2.667,P = 0.015)。
要点
- EPS在伴有淋巴血管侵犯、脏层胸膜侵犯和气道播散的肿瘤中显著升高(P < 0.001)。
- EPS是无进展生存期的独立预测因子(HR = 2.667,P = 0.015)。
- 基于EPS的列线图在TCIA验证队列中预测1年、3年和5年无进展生存期的AUC分别为0.67、0.70和0.68。
核心结论
- EPS是一种具有生物学相关性的无创影像生物标志物,可能改善非小细胞肺癌的风险分层。
研究设计与样本
- 回顾性研究,纳入244例术前行[18F]FDG PET/CT的非小细胞肺癌患者。
- 提取并标准化115个PET影像组学特征,以80:20比例划分训练8种机器学习模型预测淋巴血管侵犯、脏层胸膜侵犯和气道播散。
- 采用多变量Cox回归进行预后分析,并在TCIA队列中外部验证包含EPS的生存预测模型。
- 使用76例TCIA患者的RNA测序数据进行转录组和免疫谱分析。
主要发现
- EPS在伴有淋巴血管侵犯、脏层胸膜侵犯和气道播散的肿瘤中显著升高(P < 0.001)。
- EPS在SHAP特征重要性排序中 consistently 位居前列。
- EPS是无进展生存期的独立预测因子(HR = 2.667,P = 0.015)。
- 基于EPS的列线图在TCIA验证队列中预测1年、3年和5年无进展生存期的AUC分别为0.67、0.70和0.68。
- 高EPS与增殖和代谢基因特征相关,低EPS与免疫激活和中性粒细胞浸润相关。
关键数值与推荐
- EPS由归一化的SUVmax至质心距离和SUVmax至周边距离计算得出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate non-invasive prediction of histopathologic invasiveness and recurrence risk remains a clinical challenge in resectable non-small cell lung cancer (NSCLC). We developed and validated the Edge Proximity Score (EPS), a novel [18F]FDG PET/CT-based spatial imaging feature that quantifies the displacement of SUVmax relative to the tumor centroid and perimeter, to assess tumor aggressiveness and predict progression-free survival (PFS). METHODS: This retrospective study included 244 NSCLC patients with preoperative [18F]FDG PET/CT. EPS was computed from normalized SUVmax-to-centroid and SUVmax-to-perimeter distances. A total of 115 PET radiomics features were extracted and standardized. Eight machine learning models (80:20 split) were trained to predict lymphovascular invasion (LVI), visceral pleural invasion (VPI), and spread through air spaces (STAS), with feature importance assessed using SHAP. Prognostic analysis was conducted using multivariable Cox regression. A survival prediction model incorporating EPS was externally validated in the TCIA cohort. RNA sequencing data from 76 TCIA patients were used for transcriptomic and immune profiling. RESULTS: EPS was significantly elevated in tumors with LVI, VPI, and STAS (P < 0.001), consistently ranked among the top SHAP features, and was an independent predictor of PFS (HR = 2.667, P = 0.015). The EPS-based nomogram achieved AUCs of 0.67, 0.70, and 0.68 for predicting 1-, 3-, and 5-year PFS in the TCIA validation cohort. High EPS was associated with proliferative and metabolic gene signatures, whereas low EPS was linked to immune activation and neutrophil infiltration. CONCLUSION: EPS is a biologically relevant, non-invasive imaging biomarker that may improve risk stratification in NSCLC.
引用
- Jiang Z, Spielvogel C, Haberl D, et al. Spatial imaging features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness. Eur J Nucl Med Mol Imaging. 2025. PMID: 40839309. doi:10.1007/s00259-025-07528-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。